MarineMax, Inc. filed an 8-K on November 12, 2026, reporting the results of a special shareholder meeting held November 11, 2026, at which shareholders voted to approve the company's proposed merger with an affiliate of Safe Harbor Marinas, LLC.
Edgewell Personal Care Company filed a Form 8-K on November 12, 2026, announcing the release of financial and operating results for its fourth quarter and fiscal year ended September 30, 2026.
Tetra Tech, Inc. filed a Form 8-K on November 12, 2026, reporting its fourth fiscal quarter financial results for the period ended September 27, 2026, and announcing a quarterly cash dividend declaration by its Board of Directors.
Murphy Oil Corporation filed a Form 8-K with the SEC on November 12, 2026, disclosing two separate exploration and production agreements: six exploration licenses awarded in Israel's Zone G and four production sharing contracts covering offshore Cameroon blocks.
Vylor Inc. filed a Form 8-K on November 12, 2026, attaching unaudited pro forma consolidated financial statements reflecting its separation from Corteva, Inc., which was completed on October 1, 2026.
CXJ Group Co., Limited filed a Form 8-K on November 12, 2026, disclosing the resignation of its independent registered public accounting firm, J & S Associate PLT., and the appointment of WSJ and Partners as its replacement.
Quetta Acquisition Corporation filed a Form 8-K on November 12, 2026, disclosing that a $5,000 Extension Payment was deposited into its trust account on November 9, 2026, extending the deadline to complete its initial business combination by one month.
GeoVax Labs, Inc. filed a Form 8-K with the SEC on November 12, 2026, disclosing that the company completed a 1-for-24 reverse stock split of its common stock effective November 10, 2026.
Chan Chun Hong filed a Schedule 13G with the SEC on November 12, 2026, disclosing beneficial ownership of 520,834 shares of Addentax Group Corp. common stock, representing 16.55% of the class as of November 11, 2026.
enGene Therapeutics Inc. filed a Form 8-K on November 12, 2026, reporting pivotal Phase 2 LEGEND trial results for detalimogene, FDA alignment on a planned Biologics License Application, and preliminary fiscal year-end cash of approximately $245.8 million.